May 25, 2016
3 min watch
Save
This article is more than 5 years old. Information may no longer be current.
VIDEO: Recently approved Nuplazid fills treatment gap in Parkinson’s disease
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
ATLANTA — Henry Nasrallah, MD, of the department of neurology and psychiatry at St. Louis University, discusses the utility of the recently FDA-approved Nuplazid for psychosis in Parkinson’s disease.
“Parkinson’s disease has many non-motor psychiatric symptoms, including psychosis. Up to 50% of Parkinson’s patients develop psychotic symptoms, which are predominantly visual hallucinations as well as delusions,” Nasrallah told Healio.com/Psychiatry. “These are obviously very disruptive symptoms and they get worse as disease progresses.”
Until now, there has been no medication intended for psychosis in Parkinson’s disease, according to Nasrallah.